Claims for Patent: 8,481,064

Summary for Patent: 8,481,064

Title:	Method for delivering a therapeutic agent comprising injection of microspheres
Abstract:	The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.
Inventor(s):	McKay; William F. (Memphis, TN)
Assignee:	Warsaw Orthopedic, Inc. (Warsaw, IN)
Application Number:	12/715,093
Patent Claims:	1. A method for delivering a therapeutic agent to a targeted tissue site, the method comprising injecting into the targeted tissue site a drug depot comprising a body having opposite sides and at least two angled flexible barbs extending from the opposite sides of the body, wherein the drug depot comprises a plurality of microspheres encapsulating the therapeutic agent, and the drug depot is configured to release the microspheres in the targeted tissue site. 2. The method of claim 1 wherein the targeted tissue site is the annulus fibrosus. 3. The method of claim 1 wherein the targeted tissue site is the nucleus pulposus. 4. The method of claim 1 wherein the therapeutic agent is an anti-inflammatory agent. 5. The method of claim 4 wherein the anti-inflammatory agent is specific for a target selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF. 6. The method of claim 1 wherein the therapeutic agent is an osteoinductive growth factor. 7. The method of claim 6 wherein the osteoinductive growth factor is selected from the group consisting of BMP-1, BMP-2, rhBMP-2, BMP-3, BMP-4, rhBMP-4, BMP-5, BMP-6, rhBMP-6, BMP-7 (0P-1), rhBMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, GDF-5, LIM mineralization protein, platelet derived growth factor (PDGF), transforming growth factor f3 (TGF-f3), insulin-related growth factor-I (IGF-I), insulin-related growth factor-II (IGF-II), fibroblast growth factor (FGF), beta-2-microglobulin (BDGF II), and rhGDF-5. 8. The method of claim 1 wherein the therapeutic agent is a kinase inhibitor. 9. The method of claim 8 wherein the kinase inhibitor is selected from the group consisting of Gleevec, Herceptin, Iressa, imatinib (STI571), herbimycin A, tyrphostin 47, erbstatin, genistein, staurosporine, PD98059, SB203580, CNI-1493, VX-50/702, SB203580, BIRB 796, Glaxo P38 MAP Kinase inhibitor, RWJ67657, U0126, Gd, SC10-469, RO3201195, and Semipimod. 10. The method of claim 1 wherein the therapeutic agent is ISIS2302 or GI 129471. 11. The method of claim 1 wherein the plurality of microspheres have a particle size range of from about 8 .mu.m to about 15 .mu.m. 12. The method of claim 11 wherein the plurality of microspheres are lipid containing microspheres. 13. The method of claim 1, wherein the plurality of microspheres have a particle size range of from about 5 .mu.m to about 30 .mu.m. 14. The method of claim 1, wherein the at least two angled flexible barbs are part of an anchoring system which provides a surface adapted to abut against a tissue. 15. The method of claim 14, wherein the anchoring system further comprises an end cap disposed on an end of the body of the drug depot. 16. The method of claim 1, wherein the at least two angled flexible barbs also comprise a plurality of microspheres. 17. The method of claim 1, wherein each of the at least two angled flexible barbs comprises a point adapted to allow forward translational movement of the body and limit backward translational movement of the body from the targeted tissue. 18. The method of claim 1, wherein the at least two angled flexible barbs are configured to release the microspheres into the targeted tissue site.

Details for Patent 8,481,064

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26